PROTECHT Score Calculator

Clinical calculation support · Verify results before clinical use

Cancer-Associated VTE Risk Assessment

Enter the patient's pre-chemotherapy characteristics and planned chemotherapy regimen. The score updates automatically.

0 Total score

Primary cancer site

Select the category corresponding to the primary malignancy.

0–2 points

Pre-chemotherapy platelet count

Use the platelet count measured before chemotherapy.

+1 point

Hemoglobin or erythropoiesis-stimulating agent use

Count this criterion if hemoglobin is below 10 g/dL or an erythropoiesis-stimulating agent is used.

+1 point

Pre-chemotherapy white blood cell count

Threshold: greater than 11 × 10⁹/L.

+1 point

Body mass index (BMI)

Threshold: BMI ≥35 kg/m².

+1 point

Platinum-based chemotherapy

Examples include cisplatin or carboplatin regimens.

+1 point

Gemcitabine chemotherapy

Score this separately; a regimen containing both platinum and gemcitabine contributes one point for each criterion.

+1 point
0 PROTECHT
Risk classification threshold
Below high-risk threshold
Score below 3 points; this is not a guarantee of low individual VTE risk.
Clinical interpretation

Use the score alongside clinical assessment and bleeding risk when considering thromboprophylaxis.

The commonly used PROTECHT threshold identifies a score ≥3 as high risk. Risk scores have imperfect discrimination and should not independently determine anticoagulant prophylaxis.

About the PROTECHT score

The PROTECHT score is a modified Khorana risk assessment model for chemotherapy-associated venous thromboembolism (VTE) in ambulatory patients with cancer. It retains the five Khorana components and adds one point for platinum-based chemotherapy and one point for gemcitabine chemotherapy.

Scoring criteria

VariableCriterionPoints
Pancreas or stomach cancerVery-high-risk tumor site+2
Lung, lymphoma, gynecologic, bladder, or testicular cancerHigh-risk tumor site+1
Platelet count≥350 × 10⁹/L before chemotherapy+1
Hemoglobin / ESAHemoglobin <10 g/dL or erythropoiesis-stimulating agent use+1
White blood cell count>11 × 10⁹/L before chemotherapy+1
BMI≥35 kg/m²+1
Platinum-based chemotherapyPlanned or received+1
Gemcitabine chemotherapyPlanned or received+1

Interpretation

A score of 3 or more is commonly used as the high-risk threshold in research and risk-stratification practice. A score below 3 does not exclude VTE risk. The score is a risk assessment aid, not a diagnostic test for existing thrombosis.

References

Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the PROTECHT score. Internal and Emergency Medicine. 2012;7(3):291–292. DOI: 10.1007/s11739-012-0784-y; PMID: 22547369.
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–4907. DOI: 10.1182/blood-2007-10-116327; PMID: 18216292.
Guman AM, van Geffen RJ, Mulder FI, et al. Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancer. Journal of Thrombosis and Haemostasis. 2021;19(12):2974–2983. DOI: 10.1111/jth.15503; PMID: 34409743.
Clinical disclaimer: This calculator is intended to support, not replace, clinical judgement. Consider cancer type and stage, treatment plan, patient preferences, renal function, drug interactions, thrombocytopenia, bleeding risk, and applicable guidelines before prescribing thromboprophylaxis. Do not use this score to diagnose or exclude an existing VTE.